Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis

  • Technology appraisal guidance
  • TA320
  • Published: 

History

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: equality impact assessment - guidance development

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: final appraisal determination

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: appraisal consultation

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: response to comments on the draft scope and provisional matrix

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: final matrix

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: final scope

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: draft scope for consultation (post-referral)

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: provisional matrix for consultation (post-referral)

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: draft scope - (pre referral)

Multiple sclerosis (relapsing-remitting) - dimethyl fumarate: provisional matrix - (pre referral)